t-cell engagers vs monoclonal antibodies for the treatment of aml: the influence of cd38 expression
Published 7 months ago • 138 plays • Length 1:59Download video MP4
Download video MP3
Similar videos
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
1:24
t-cell engaging antibodies: what lessons have we learnt?
-
3:27
the mechanism of bispecific t-cell engagers in b-all: genomic alterations
-
2:41
cell avidity as a predictor of t-cell efficacy
-
5:35
clinical and prognostic significance of aberrant t-cell marker expression in aml
-
1:32
label-free live cell imaging of mesenchymal stem cells undergoing mitosis
-
5:01
b cells vs t cells | b lymphocytes vs t lymphocytes - adaptive immunity - mechanism
-
3:05
the development of inkt-car t-cells for hematological malignancies
-
1:31
pegenzileukin for t-cell dysfunction
-
2:13
haploidentical sct for the treatment of secondary aml
-
1:19
single-cell sequencing of circulating tumor cells to predict progression from mgus/smm
-
2:18
redirecting t-cell cytotoxicity and proliferation
-
0:16
label-free live cell imaging: activated t-cell killing cancer cell
-
1:54
investigating the combination of tolinapant & decitabine in a pre-clinical model for t-cell lymphoma
-
2:58
bcma 2 1 t-cell engager cc-93269 in patients with r/r myeloma
-
7:34
immunotherapy for t-cell malignancies
-
8:57
outcomes of sct in t-all and t-lbl
-
1:12
an update in cellular therapies: gene editing for scd and immunotherapies for mm
-
1:38
genome editing tools in t cell-based immunotherapies
-
1:47
identifying positive regulators of t cell functions to improve cellular therapies
-
4:36
rejuvinated cd8 t-cells derived from ipscs in the treatment of myeloma
-
1:10
immunotherapy and its dependence on t-cells